Announcements
Keystone Dental Announces the Initiation of Five-year, Multi-Center Postmarket Clinical Study of Genesis Implant System to Evaluate Survival, Bone-level Changes, and Soft Tissue Aesthetics
Burlington, MA, August 22, 2011 – Keystone Dental, an oral healthcare company focused on the delivery of breakthrough products to the oral healthcare space, announced today that a five-year, multi-center study to evaluate the long-term success of Genesis, The Biomimetic Implant System™, will begin this week. This postmarket surveillance study will evaluate both the long-term clinical and aesthetic success of the novel Genesis Implant System.
"We are thrilled to kick off this much anticipated study," said Pascal Girin, President and CEO of Keystone Dental, "especially given the caliber of clinicians participating in the study, including Dr. Dennis P. Tarnow as the lead investigator. We see this postmarket study as an example of the commitment we have made to delivering strong clinical evidence to the dental community."
The study will be conducted at eight centers within the United States with a total expected enrollment of approximately 120 patients. Genesis dental implants will be surgically placed and assessed at defined time points beginning one year post surgery. Additional safety and performance endpoints for the Genesis Implant System will be evaluated, including changes in bone height and soft tissue aesthetic outcomes.
"We know the design of the Genesis Implant System offers a number of significant advantages including an advanced surface, an aggressive thread design, and the first-ever marketed pink implant collar and abutment to improve aesthetic success," said Dr. Mariano Polack, DDS, MS, Prosthodontist, "and this study will demonstrate how it behaves long term, which is incredibly important information to the practicing clinician."
Keystone Dental is an oral healthcare company dedicated to the delivery of breakthrough technology. Keystone Dental’s product portfolio includes Genesis, The Biomimetic Implant System™, The Prima™ Implant System, DynaMatrix® Extracellular Membrane, DynaBlast® and DynaGraft® bone graft substitutes, and Accell Connexus™, a next-generation bioactive bone grafting product. Founded in 2006, Keystone Dental’s vision is to be a trusted oral healthcare partner focused on breakthrough technologies, whose goal is to inspire customers, instill pride in its employees, and deliver value every day.
Oxford Finance LLC Provides $20 Million Growth Capital Loan to Keystone Dental, Inc.
ALEXANDRIA, Va., Aug. 16, 2011 -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced that it closed a $20 million senior secured term loan with Keystone Dental, Inc. Proceeds of the loan were used to pay off an existing line of credit and fund growth and working capital. View Press Release.
Pascal Girin Appointed President, Chief Executive Officer and Director of Keystone Dental, Inc.
On February 17, 2011, Keystone Dental, Inc. appointed Pascal Girin as President, Chief Executive Officer and Director. Mr. Girin succeeds Dan Levangie, who will continue to serve the company in his new role as Chairman of the Board of Directors.
Mr. Girin has served as Executive Vice President and Chief Operating Officer of Keystone since October 2010. Prior to joining Keystone, Mr. Girin served as Chief Operating Officer of ev3 Inc., a global leader in technologies and solutions for the treatment of peripheral vascular and neurovascular diseases, from the date of its acquisition by Covidien Group in July 2010 until September 2010. Prior to that, he served as ev3 Inc.’s Executive Vice President and Chief Operating Officer from January 2010 until July 2010, its Executive Vice President and President, Worldwide Neurovascular and International from July 2008 to January 2010, the Senior Vice President and President, International of ev3 International from July 2005 to July 2008, and the General Manager, Europe of ev3 Inc. from September 2003 to July 2005. Prior to joining ev3, Inc., Mr. Girin served in various capacities at BioScience Europe Baxter Healthcare Corporation from September 1998 until August 2003. He received an engineering education at the French Ecole des Mines. Mr. Girin also serves as a director for Tornier, Inc., which designs, manufactures and markets devices for joint replacement and soft tissue repair.
DynaMatrix® Featured on Discovery Channel Segment Highlighting Innovative Products in Oral Health
DynaMatrix® Extracellular Membrane, Keystone Dental's soft tissue regeneration product, was featured on the Discovery Channel in an episode of Health Heroes. The episode focused on innovative products in oral health and highlighted DynaMatrix® as an alternative to using a soft tissue graft taken from the roof of the patient’s mouth to preserve teeth by treating gum recession.
To read more and watch the video, click here.